AMY MCGUIRE to Cost-Benefit Analysis
This is a "connection" page, showing publications AMY MCGUIRE has written about Cost-Benefit Analysis.
Connection Strength
0.200
-
Short-term costs of integrating whole-genome sequencing into primary care and cardiology settings: a pilot randomized trial. Genet Med. 2018 12; 20(12):1544-1553.
Score: 0.117
-
Family-level impact of genetic testing: integrating health economics and ethical, legal, and social implications. Per Med. 2021 05; 18(3):209-212.
Score: 0.036
-
The Clinical Sequencing Evidence-Generating Research Consortium: Integrating Genomic Sequencing in Diverse and Medically Underserved Populations. Am J Hum Genet. 2018 09 06; 103(3):319-327.
Score: 0.030
-
Overview of the arthritis Cost Consequence Evaluation System (ACCES): a pharmacoeconomic model for celecoxib. Rheumatology (Oxford). 2000 Dec; 39 Suppl 2:33-42; discussion 57-9.
Score: 0.009
-
Cost-effectiveness of different ACE inhibitor treatment scenarios post-myocardial infarction. Eur Heart J. 1997 Sep; 18(9):1411-5.
Score: 0.007